Are Weight-Loss Stocks Finally a Buy?

For hump Wednesday, I am asking the question on whether the two premier diet drug companies are finally over the hump and have stopped the bleed?WEIGHT-LOSS DRUG COVERAGE RISES AMONG LARGE US EMPLOYERS IN 2024: MERCER SURVEY 44% of US employers with 500+ employees now cover weight-loss drugs, up from 41% in 2023. Among employers with over 20,000 employees, 64% offer coverage, compared to 56% last year. Coverage includes GLP-1 drugs like Wegovy and Zepbound , shown to reduce weight by 15-20%.

Plus, I cannot help but perseverate on the domino effect of a percentage of the population thinner, now wanting to do injectables, use better skin care products, wear more makeup, buy better clothes, go to the gym, and so on..Novo-Nordisk also had a clear reversal bottom low on Monday.Real Motion never flashed a Bonafide mean reversion. However, the Leadership indicator tells us that NVO’s performance is not too far behind the benchmarks.

Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.would like to remind you that the data contained in this website is not necessarily real-time nor accurate.

It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Nederland Laatste Nieuws, Nederland Headlines

Similar News:Je kunt ook nieuwsberichten lezen die vergelijkbaar zijn met deze die we uit andere nieuwsbronnen hebben verzameld.

Biotech Stocks About to Make a Seasonal Move Higher? Here's How to Spot a BreakoutStocks Analysis by Michele Schneider covering: S&P 500, iShares Biotechnology ETF. Read Michele Schneider's latest article on Investing.com
Bron: Investingcom - 🏆 450. / 53 Lees verder »

ARKK Set for a Breakout? Why Cathie Woods Fund Could Shine in the 2024 Bull MarketStocks Analysis by Michele Schneider covering: ARK Innovation ETF. Read Michele Schneider's latest article on Investing.com
Bron: Investingcom - 🏆 450. / 53 Lees verder »

Could Cannabis Stocks Stage a Comeback in Trump's New Term?Stocks Analysis by Michele Schneider covering: AdvisorShares Pure US Cannabis ETF. Read Michele Schneider's latest article on Investing.com
Bron: Investingcom - 🏆 450. / 53 Lees verder »

What Is the High Yield to Debt Bonds Ratio Saying About Market Sentiment?Bonds Analysis by Michele Schneider covering: iShares iBoxx $ High Yield Corporate Bond ETF. Read Michele Schneider's latest article on Investing.com
Bron: Investingcom - 🏆 450. / 53 Lees verder »